进展型多发性硬化症的临床试验:进展、新经验与剩余挑战
尽管复发型多发性硬化症的疾病修正治疗取得成功,许多患者的进展性残疾仍在累积。自2014年以来,几种免疫调节方法获批用于进展型多发性硬化症,主要针对活动性炎症患者,其获批需要大型3期试验。新药类别如布鲁顿酪氨酸激酶抑制剂即将完成试验阶段,多种神经保护候选化合物在2期试验中取得成功,髓鞘再生创新方法正在临床试验中探索。
要点
- 自2014年以来,几种免疫调节方法获批用于进展型多发性硬化症,主要针对活动性炎症患者。
- 布鲁顿酪氨酸激酶抑制剂等新药类别即将完成试验阶段,多种神经保护候选化合物在2期试验中取得成功。
- 患者组织、制药公司和学术研究者的合作对维持试验势头和产生相关结果至关重要。
核心结论
- 尽管复发型多发性硬化症的疾病修正治疗取得成功,许多患者的进展性残疾仍在累积,中断进展的复杂病理过程仍是持续挑战。
研究设计与样本
- 综述,检索范围未报告。
主要发现
- 自2014年以来,几种免疫调节方法获批用于进展型多发性硬化症,主要针对活动性炎症患者,其获批需要大型3期试验。
- 新药类别如布鲁顿酪氨酸激酶抑制剂即将完成试验阶段,多种神经保护候选化合物在2期试验中取得成功,髓鞘再生创新方法正在临床试验中探索。
- 正在定义可在2期试验中比残疾指标更快提供结果的中间结局,多臂多阶段和无效性方法等更高效试验设计正被越来越多地使用。
关键数值与推荐
- 自2014年以来获批的免疫调节方法具有 modest 但临床有意义的效果,主要针对活动性炎症患者。
- 获批需要大型3期试验,有足够把握度检测对残疾的有意义效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the success of disease-modifying treatments in relapsing multiple sclerosis, for many individuals living with multiple sclerosis, progressive disability continues to accrue. How to interrupt the complex pathological processes underlying progression remains a daunting and ongoing challenge. Since 2014, several immunomodulatory approaches that have modest but clinically meaningful effects have been approved for the management of progressive multiple sclerosis, primarily for people who have active inflammatory disease. The approval of these drugs required large phase 3 trials that were sufficiently powered to detect meaningful effects on disability. New classes of drug, such as Bruton tyrosine-kinase inhibitors, are coming to the end of their trial stages, several candidate neuroprotective compounds have been successful in phase 2 trials, and innovative approaches to remyelination are now also being explored in clinical trials. Work continues to define intermediate outcomes that can provide results in phase 2 trials more quickly than disability measures, and more efficient trial designs, such as multi-arm multi-stage and futility approaches, are increasingly being used. Collaborations between patient organisations, pharmaceutical companies, and academic researchers will be crucial to ensure that future trials maintain this momentum and generate results that are relevant for people living with progressive multiple sclerosis.
引用
- Chataway J, Williams T, Li V, et al. Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges. Lancet Neurol. 2024. PMID: 38365380. doi:10.1016/S1474-4422(24)00027-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。